127 related articles for article (PubMed ID: 27712589)
1. Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells.
Isono M; Sato A; Okubo K; Asano T; Asano T
Oncol Res; 2016; 24(5):327-335. PubMed ID: 27712589
[TBL] [Abstract][Full Text] [Related]
2. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Sato A; Asano T; Isono M; Ito K; Asano T
BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
[TBL] [Abstract][Full Text] [Related]
3. Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells.
Isono M; Sato A; Asano T; Okubo K; Asano T
Anticancer Res; 2018 Jun; 38(6):3493-3500. PubMed ID: 29848702
[TBL] [Abstract][Full Text] [Related]
4. The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells.
Okubo K; REßING N; Schulz WA; Hansen FK; Asano T; Sato A
Anticancer Res; 2021 Dec; 41(12):5987-5996. PubMed ID: 34848452
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.
Kim MJ; Lee JS; Park SE; Yi HJ; Jeong IG; Kang JS; Yun J; Lee JY; Ro S; Lee JS; Choi EK; Hwang JJ; Kim CS
J Urol; 2015 May; 193(5):1660-8. PubMed ID: 25433307
[TBL] [Abstract][Full Text] [Related]
6. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
Sato A; Asano T; Ito K; Asano T
Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
[TBL] [Abstract][Full Text] [Related]
7. Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress.
Sato A; Asano T; Okubo K; Isono M; Asano T
Oncol Res; 2018 Mar; 26(2):323-332. PubMed ID: 28560953
[TBL] [Abstract][Full Text] [Related]
8. Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells.
Okubo K; Isono M; Miyai K; Asano T; Sato A
Cancer Sci; 2020 Jan; 111(1):112-126. PubMed ID: 31675763
[TBL] [Abstract][Full Text] [Related]
9. Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
Okubo K; Isono M; Asano T; Sato A
Anticancer Res; 2018 Oct; 38(10):5615-5626. PubMed ID: 30275179
[TBL] [Abstract][Full Text] [Related]
10. Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation.
Sato A; Asano T; Okubo K; Isono M; Asano T
Cancer Sci; 2017 Jun; 108(6):1194-1202. PubMed ID: 28342223
[TBL] [Abstract][Full Text] [Related]
11. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
Dovzhanskiy DI; Arnold SM; Hackert T; Oehme I; Witt O; Felix K; Giese N; Werner J
BMC Cancer; 2012 Jun; 12():226. PubMed ID: 22681698
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
[TBL] [Abstract][Full Text] [Related]
13. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Sato A; Asano T; Ito K; Sumitomo M; Asano T
BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
15. Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells.
Sato A; Asano T; Horiguchi A; Ito K; Sumitomo M; Asano T
Urology; 2010 Sep; 76(3):764.e7-13. PubMed ID: 20630573
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.
Sato A; Asano T; Horiguchi A; Ito K; Sumitomo M; Asano T
Oncol Res; 2011; 19(5):217-23. PubMed ID: 21542457
[TBL] [Abstract][Full Text] [Related]
17. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
18. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
[TBL] [Abstract][Full Text] [Related]
19. 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
Sato A; Asano T; Ito K; Asano T
Int J Oncol; 2012 Jul; 41(1):46-52. PubMed ID: 22470109
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis.
Hamam HJ; Palaniyar N
Biomolecules; 2019 May; 9(5):. PubMed ID: 31083537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
